GLP-1 week one: what first-week results actually mean

What did @deliaochoapat actually say?

Honestly? Very little that can be fact-checked. The transcript captured from this video reads as a string of what appear to be game or app sound cues: "Tengyae, Tuan, Linong, Game Linong, Game, Game Start." There are no medical claims, no dosing information, no descriptions of side effects or results. The caption says "Primera semana" (first week) with a sparkle emoji, which suggests this is a week-one GLP-1 journey update, but the spoken content doesn't confirm or deny anything about the medication, its effects, or the creator's experience with it.

The hashtags place this in Cuenca, Ecuador, and the category tag flags it as GLP-1 related. But the audio, as transcribed, doesn't contain verifiable health claims. This may be a silent or background-audio video where the real content is visual, not spoken.

Does the science back this up?

There's nothing in the transcript to evaluate scientifically. That's not a dismissal of the video's potential value. It's just the reality of what was captured. GLP-1 receptor agonists like semaglutide and tirzepatide have a substantial evidence base. Week-one experiences, however, are highly variable and rarely predictive of long-term outcomes.

What we do know from the literature is that the first week on a GLP-1 medication is often dominated by gastrointestinal side effects rather than weight loss. A 2022 trial by Wilding et al. in the New England Journal of Medicine showed that semaglutide's meaningful weight reduction typically emerges over weeks and months, not days. If this creator is documenting week one, the honest clinical story would likely involve nausea, appetite suppression, and very modest scale movement at best. Anyone watching this expecting dramatic first-week results from GLP-1 therapy should temper those expectations with actual trial data.

What did they get wrong (or right)?

Without substantive spoken claims, there's nothing to mark as wrong or right. What this video does do, unintentionally or not, is contribute to a genre of GLP-1 content that packages personal experience as implicit endorsement. The sparkle emoji and "first week" framing creates a narrative of excitement and optimism that viewers may project outcomes onto, even when nothing specific is said.

That framing isn't necessarily dishonest. Personal journey content has legitimate value. But in the GLP-1 space, where viewers are often making consequential health decisions based on social media, the absence of context is its own kind of problem. No mention of prescriber oversight, no acknowledgment of side effects, no clarification about which specific medication or formulation is being used. The video is neither accurate nor inaccurate. It's simply empty of checkable content, which in a medically sensitive category deserves naming plainly.

What should you actually know?

If you're starting a GLP-1 medication and looking to this kind of content for guidance, here's what the evidence actually says about week one. Nausea affects a significant proportion of patients early on. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) reported gastrointestinal adverse events as the most common reason for discontinuation in tirzepatide users. Starting low and titrating slowly is the clinical standard precisely because the first weeks are a physiological adjustment period, not a results window.

Weight loss in week one is largely water weight and glycogen depletion, not fat loss. Meaningful body composition changes take time. Anyone selling you a dramatic first-week transformation story on GLP-1s is either unusually lucky or not being straight with you. Document your own experience, yes. But cross-reference it with your prescriber and with peer-reviewed data, not just TikTok sparkle emojis.